The international pharmaceutical company Ferrer has announced the extension of its phase III clinical trial ADORE, with FNP122 in amyotrophic lateral sclerosis.
The international pharmaceutical company Ferrer has announced the extension of its phase III clinical trial ADORE, with FNP122 in amyotrophic lateral sclerosis.